In Episode 17, we talk about approval of Ayvakit for the treatment of specifically mutated GIST, FDA statement regarding the risk of cancer while taking Belviq, and approval of Mycamine for pediatric patients less than 4 months. We also go over two topics this week, the FDA fight against e-cigarettes, and California potentially becoming the next big generic manufacturer. Don't forget to share and subscribe!

We've made it to the 1st full week of 2020! In episode 16, we talk about new indications for Fiasp & Keytruda as well as threats by the FDA to generic drug manufacturers. We also talk about HR5534, a new bill introduced into legislation that would expand access to transplant medications for medicare recipients. Don't forget to share this with anyone who wants to get regular updates on new products coming to market! Enjoy!

Our first episode of 2020! In Episode 15 we discuss multiple approvals by the FDA including Ervebo for treatment of Ebola Virus Disease, Ubrelvy for treatment of migraines in adults, Dayvigo for insomnia (clever name... get it?), and Caplyta for treatment of schizophrenia in adults. We also discuss added indication for Lynparza, and a new treatment called Enhertu for HER2 positive breast cancer. Happy New Year!

In episode 14 we discuss approval of Padcev for urothelial cancer, Vyondys 53 for Duchenne Muscular dystrophy, added indications for Xtandi and Xeljanz XR, and approval of Vascepa to reduce the risk of cardiovascular events. Have a great holiday season everyone!

In episode 13 we talk about approval of a new biosimilar for Remicade, called Avsola; the US market launch of a Herceptin biosimilar, Ogivri; the first generics for Gilenya being approved, and a new approved indication for Tecentriq.

In episode 12 we talk about approval of Givlaari for acute hepatic porphyria, a second approval for sickle cell disease, a new formulation of an old product for ALS, the 26th biosimlar approved in the US, and approval of Calquence for CLL & SLL. We also talk about updated recommendations on pneumococcal vaccination from the CDC (PCV13)

In episode 11 we talk about approval of Rebloyzl for beta thalassemia, new product Brukinsa for mantle cell lymphoma, Fetroja for complicated UTI, Adakveo for sickle cell disease, and Xcopri for partial onset seizures.

In episode 10 we talk about approval of Talicia and Ziextenzo by the FDA and approval of Fluzone HD quadrivalent vaccine for the 2020/2021 flu season. We'll be back with a new episode on November 22nd!

In episode 9 - a short week for the FDA, we talk about approval of Liletta for pregnancy prevention up to 6 years, Vumerity was approved for multiple sclerosis (MS), and added indication for Baxdela. We also give a brief update on new biosimilars expected in the next few months, and a new recall on alprazolam.

In this episode we discuss new drug approvals for cystic fibrosis (Trikafta), and a new topical acne treatment (Amzeeq). We also talk about updated indications for Farxiga and Stelara, as well as updates to USP 795 and 797.